Influence of Inhaler Compliance on the Treatment of Asthma Patients

Sponsor
Taipei Medical University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06108908
Collaborator
Taipei Medical University (Other)
150
1
60.6
2.5

Study Details

Study Description

Brief Summary

The major goal of "Influence of Inhaler Compliance on the Treatment of Asthma Patients" is to explore compliance rate outcome in adult asthmatic patients (20-80 years old) with mild to moderate persistent asthma according to American Thoracic Society (ATS) definition and diagnosis. The major endpoints include:

  1. To increase the adherence rate of treatment by reminder intervention with correctly monitor patients' adherence rate by Asthma Supportive Kits

  2. Eventually achieve best asthma care and management.

All participants will use Asthma Supportive Kits for 24 weeks and return visit on week 5, 12, 24. Based on collected data, the study compares intervention and control group to see if active reminder intervention may effectively alter compliance rate, and corresponding outcomes, e.g., asthma control status, acute exacerbation events.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Reminder

Detailed Description

  1. Upon enrollment, the all patients will be educated and equipped with asthma supportive kits, which is a electronic device attaches to an MDI medicine.

  2. The asthma supportive kit registers every puff taken when the patient uses his/her MDI. The records are monitored by study nurses and calculated compliance ratio on rolling basis.

  3. By enrollment, the patient is RANDOMLY assigned to Intervention and Control group. For the Intervention group in each study phases, when the given compliance ratio drops below 80% (as monitored by asthma supportive kit), the study nurse will actively engage to remind on medicine taking. For the Control group, the compliance ratio is calculated but to active engagement is applied.

  4. All the patients adheres with regular asthma treatment mechanism, regardless to group assigned.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Influence of Inhaler Compliance on the Treatment of Asthma Patients
Actual Study Start Date :
Aug 14, 2019
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Aug 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Intervention Group

Patients (compliance rate <80%) received active contact to remind on regular use of medication. The intervention is engaged in caring aspect behavior. None of regular asthma treatment is altered between groups.

Behavioral: Reminder
1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.

Control

Patients were not informed regardless to their compliance rate.

Behavioral: Reminder
1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.

Outcome Measures

Primary Outcome Measures

  1. compliance ratio [28 day]

    Compliance Ratio: the Compliance Ratio evaluates the ratio of days which the patient is taking equal (or greater than) puffs of medicine as instructed by physician with the past 28-days. the outcome ratio ranges from 0% (none of days is taking correct amount) to 100% (all past 28 days were taking correct amount).

  2. Asthma Control Test Score [28 day]

    Asthma Control Test (ACT) Score: the ACT is a patient self-administrated tool for identifying those with poorly controlled asthma; the test includes 5 items to recall past 4-week symptoms and daily functioning; The scores range from 5 as poorly controlled to 25 as completely controlled of asthma

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adult asthmatic patients (20-80 years old)

  2. With mild to moderate persistent asthma according to ATS definition and diagnosis

  3. Willing to use Budesonide+Formoterol.

  4. Adequately use inhaler

  5. Without evident intentional non-adherence

  6. Agree asthma is a common and potentially serious chronic disease

  7. Willing to sign Informed Consent Form

Exclusion Criteria:
  1. Inadequately use inhaler

  2. Disagree asthma is a common and potentially serious chronic disease

  3. With uncontrolled systemic diseases, such as hypertension, heart failure, renal failure, de-compensated liver cirrhosis, etc.;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei Medical University, Taiwan, R.O.C. Taipei Taiwan

Sponsors and Collaborators

  • Taipei Medical University Hospital
  • Taipei Medical University

Investigators

  • Principal Investigator: Han-Pin KUO, Taipei Medical University, Taiwan, R.O.C.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taipei Medical University Hospital
ClinicalTrials.gov Identifier:
NCT06108908
Other Study ID Numbers:
  • N201905051
First Posted:
Oct 31, 2023
Last Update Posted:
Oct 31, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 31, 2023